Abstract:Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely available and cost-effective modalities for diagnosis and prognosis. Recently, the blood-based AD biomarker field has seen significant progress driven by technological advances, mainly improved analytical sensitivity and precision of the assays and measurement platforms. Several blood-based biomarkers have shown high potential for accurately detecting AD pathophysiology. As a result, there has been considerable interest in applying these biomarkers for diagnosis and prognosis, as surrogate metrics to investigate the impact of various covariates on AD pathophysiology and to accelerate AD therapeutic trials and monitor treatment effects. However, the lack of standardization of how blood samples and collected, processed, stored analyzed and reported can affect the reproducibility of these biomarker measurements, potentially hindering progress toward their widespread use in clinical and research settings. To help address these issues, we provide fundamental guidelines developed according to recent research findings on the impact of sample handling on blood biomarker measurements. These guidelines cover important considerations including study design, blood collection, blood processing, biobanking, biomarker measurement, and result reporting. Furthermore, the proposed guidelines include best practices for appropriate blood handling procedures for genetic and ribonucleic acid analyses. While we focus on the key blood-based AD biomarkers for the AT(N) criteria (e.g., amyloid-beta [Aβ]40, Aβ42, Aβ42/40 ratio, total-tau, phosphorylated-tau, neurofilament light chain, brain-derived tau and glial fibrillary acidic protein), we anticipate that these guidelines will generally be applicable to other types of blood biomarkers. We also anticipate that these guidelines will assist investigators in planning and executing biomarker research, enabling harmonization of sample handling to improve comparability across studies.

ADNI Biomarker Core: A review of progress since 2004 and future challenges

The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

Contributions of the ADNI Biostatistics Core

The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

The origins of ADNI

Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative

Overview of ADNI MRI

The role of the Alzheimer's Association in the genesis of Alzheimer's Disease Neuroimaging Initiative

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

The Alzheimer's Disease Neuroimaging Initiative Positron Emission Tomography Core

Benchmarking of a multi-biomarker low-volume panel for Alzheimer's Disease and related dementia research

Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications

Benchmarking of a multi-biomarker low-volume panel for Alzheimers Disease and related dementia research

Timing of Alzheimer's disease biomarker progressions: A two‐decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease